Koyfin Home > Directory > Health Care > Adamas Pharma > Long-Term Debt / Capital

Adamas Pharma Long-Term Debt / Capital Chart (ADMS)

Adamas Pharma annual/quarterly Long-Term Debt / Capital from 2017 to 2020.
  • Adamas Pharma Long-Term Debt / Capital for the quarter ending June 06, 2020 was $119m a 28.31% increase of 34m year over year
  • Adamas Pharma Long-Term Debt / Capital for the last 12 months ending June 06, 2020 was $119m a 28.31% increase of 34m year over year
  • Adamas Pharma Annual Long-Term Debt / Capital for 2019 was $98m a 42.62% increase of 42m from 2018
  • Adamas Pharma Annual Long-Term Debt / Capital for 2018 was $56m a -8.22% decrease of -5m from 2017
  • Adamas Pharma Annual Long-Term Debt / Capital for 2017 was $61m
Other Ratios Metrics:
  • Adamas Pharma Total Debt / Capital for the quarter ending September 09, 2018 was $50m a -21.13% decrease of -11m year over year
  • Adamas Pharma Other Liabilities for the quarter ending December 12, 2018 was $3m a 76.22% increase of 2m year over year
  • Adamas Pharma Total Debt / Equity for the quarter ending September 09, 2018 was $101m a -53.94% decrease of -54m year over year
View Chart On Koyfin

Quarterly ADMS Long-Term Debt / Capital Data

06/2020$119m
03/2020$110m
12/2019$98m
09/2019$85m
06/2019$74m
03/2019$66m
12/2018$56m
09/2018$50m
06/2018$44m
03/2018$39m

Annual ADMS Long-Term Debt / Capital Data

2019$98m
2018$56m
2017$61m